cidofovir anhydrous has been researched along with Adverse Drug Event in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Adrian, J; Chen, X; Cushing, T; Dimaio, H; Jaen, J; Liang, L; Mayorga, V; Miao, S; Peterson, MG; Powers, JP; Spector, F; Stein, C; Wright, M; Xu, D; Ye, Q | 1 |
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Gündoğdu, Y; Gür, H; Kartı, SS; Koşan, B; Okuturlar, Y; Uzay, A; Yetiş, T | 1 |
Agarwal, A; Agrawal, R; Gupta, V; Mahajan, S; Marchese, A; Miserocchi, E; Testi, I | 1 |
Blanche, S; Bouazza, N; Frange, P; Hirt, D; Klifa, R; Leruez-Ville, M; Moshous, D; Neant, N; Neven, B; Treluyer, JM | 1 |
Dutton, P; Fiander, A; Griffiths, G; Hibbitts, S; Hurt, CN; Jones, S; Madden, T; Man, S; Naik, R; Nordin, AJ; Powell, N; Tristram, A | 1 |
Hong, DJ; Jhun, BW; Kim, K; Kim, SJ; Park, SB | 1 |
Czock, D; Keller, F | 1 |
Godkin, S; Lampert, B; Painter, G; Painter, W; Robertson, A; Trost, LC | 1 |
1 review(s) available for cidofovir anhydrous and Adverse Drug Event
Article | Year |
---|---|
Drug-induced Uveitis in HIV Patients with Ocular Opportunistic Infections.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antiviral Agents; Cidofovir; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Rifabutin; Uveitis | 2020 |
2 trial(s) available for cidofovir anhydrous and Adverse Drug Event
Article | Year |
---|---|
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cidofovir; Cytosine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imiquimod; Middle Aged; Neoplasm Grading; Organophosphonates; Vulvar Neoplasms | 2014 |
First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Area Under Curve; Biological Availability; Capsule Endoscopy; Cidofovir; Cytosine; DNA Viruses; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intraocular Pressure; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Placebos; United States | 2012 |
8 other study(ies) available for cidofovir anhydrous and Adverse Drug Event
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
SAR studies on a novel series of human cytomegalovirus primase inhibitors.
Topics: Administration, Oral; Animals; Antiviral Agents; Biological Availability; Cytomegalovirus; DNA Primase; DNA Replication; Drug-Related Side Effects and Adverse Reactions; Humans; Inhibitory Concentration 50; Pyrimidines; Rats; Structure-Activity Relationship; Viral Load | 2007 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Daily low dose intravesical cidofovir for the treatment of BK virus associated hemorrhagic cystitis after allogeneic stem cell transplantation.
Topics: Antiviral Agents; BK Virus; Cidofovir; Cystitis; Cytosine; Drug-Related Side Effects and Adverse Reactions; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Organophosphonates; Polyomavirus Infections; Renal Insufficiency; Tumor Virus Infections | 2023 |
Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infection.
Topics: Adenovirus Infections, Human; Antiviral Agents; Area Under Curve; Blood Chemical Analysis; Child; Child, Preschool; Cidofovir; Cytomegalovirus Infections; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunocompromised Host; Infant; Male; Models, Statistical; Treatment Outcome; Viral Load | 2018 |
Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Cidofovir; Cytosine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunocompromised Host; Medical Records; Organophosphonates; Pneumonia; Respiratory Insufficiency; Retrospective Studies; Treatment Outcome | 2015 |
[Drug-drug interactions and nephrotoxicity].
Topics: Aminoglycosides; Analgesics; Anti-Bacterial Agents; Anti-HIV Agents; Antineoplastic Agents; Antirheumatic Agents; Cidofovir; Cisplatin; Contrast Media; Creatinine; Cytosine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney; Organophosphonates; Probenecid; Risk Factors; Uricosuric Agents | 2011 |